For instance, as CD39 is also involved in the production of ADO and is expressed on the cell surface of tumor cells in human cancer cell lines including myeloma, CD39 could be a therapeutic target in overcoming resistance to current therapies for treating MM.171, 172. This evidence concerns the gene ADO and plasma cell myeloma.